Skip to main content

Table 2 Randomisation strata

From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Stratum Baseline Protease-inhibitor Regimen Use of lipid lowering therapy at study day 1 No of baseline mutations of the NRTI classa
I Atazanavir Yes < 2
II Atazanavir Yes ≥2
III Atazanavir No < 2
IV Atazanavir No ≥2
V Darunavir Yes < 2
VI Darunavir Yes ≥2
VII Darunavir No < 2
VIII Darunavir No ≥2
  1. aFrom historical genotype report assessed during screening